Company performance
Current Price
as of Jan 10, 2025$19.10
P/E Ratio
N/A
Market Cap
$2.75B
Description
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Metrics
Overview
- HQSan Francisco, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerDNLI
- Price$19.1-10.12%
Trading Information
- Market cap$2.75B
- Float86.57%
- Average Daily Volume (1m)1,110,104
- Average Daily Volume (3m)880,299
- EPS-$2.76
Company
- RevenueN/A
- Rev growth (1yr)-100.00%
- Net income-$107.19M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$121.35M
- EV$4.15B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B2.08
Documents
SEC Filings
Factset Street Account
Factset